autonomic neuropathy
Recently Published Documents


TOTAL DOCUMENTS

2170
(FIVE YEARS 344)

H-INDEX

77
(FIVE YEARS 9)

Author(s):  
Md Azad Hossain ◽  
Mukul Kumar Sarkar ◽  
Imtiaj Mahbub ◽  
SM Shahinul Islam

Background: Diabetic autonomic neuropathy (DAN) is the most neglected major and widespread microvascular complication of type-2 diabetes mellitus, involving multiple body organs. DAN is a subtype of diabetic peripheral neuropathy.Objective: To investigate the relationship between the variability of HbA1c and diabetic autonomic neuropathy in type-2 diabetes patients.Materials and methods: This study recruited a total of 150 type-2 diabetic patients to screen for diabetic autonomic neuropathy and estimated quarterly levels of HbA1c were performed within the year before enrollment. With a noninvasive procedure, DAN was validated by careful history taking, anthropometric assessment, clinical manifestations and neurological assessment.Results: Out of 150 type- 2 diabetic patients, recruited randomly, where 81 were female and 69 were male. Among all patients 29 (19.33%) had been screened positive for DAN which showed higher HbA1c than non-DAN patients. Different autonomic neuropathic dysfunction among total diabetic patients were also studies and found that the highest prevalence of sexual dysfunction among all autonomic dysfunction prevalence which is 16.66% whereas the lowest prevalence was postural hypotension that is 6.66%. The second higher prevalence is urinary incontinence (10.66%). Abnormal sweating (9.33%) and nocturnal diarrheas (7.33%) are in third and fourth position respectively. No significant (p>0.05) differences were found in the case of BMI, sex, systolic, and diastolic blood pressure between DAN and non-DAN. Data shows a major (p<0.05) risk factor for DAN has also been the prolonged period of diabetes and older age.Conclusion: The study indicates that the increased level of HbA1c in type-2 diabetic patients is closely correlated with DAN and may be considered a potent predictor of DAN in the recruited patients.International Journal of Human and Health Sciences Vol. 06 No. 01 January’22 Page: 89-95


2022 ◽  
Vol 23 (1) ◽  
pp. 67
Author(s):  
Mohammad Adil ◽  
Prateek Pathak ◽  
SyedSuhail Amin ◽  
FatimaTuz Zahra

Author(s):  
Yu.D. Udalov ◽  
L.A. Belova ◽  
V.V. Mashin ◽  
L.A. Danilova ◽  
A.A. Kuvayskaya

When studying oncology diseases, it is necessary not only to assess their nature, progress and outcome depending on the local disease process, but also to take into account overall health, since multiple organ damage has a prognostic value and determines the disease outcome. All mechanisms and structures that have an integrative and homeostatic effect on the overall health should be considered. One of these structures is the autonomic nervous system. Traditionally, the autonomic nervous system has been considered in terms of 3 components: sympathetic, parasympathetic and intestinal. However, in recent years, ideas about neuroendocrine and neuroimmune systems have come to the fore, justifying the expansion of the concept "autonomy of the nervous system." In case of autonomous dysfunction, dysregulation of the involuntary body functions occurs, and autonomic neuropathy develops. There are cardiovascular, gastrointestinal, urogenital, and sudomotor forms of autonomic neuropathy, which are characterized by certain changes in various pathological states, especially in malignant processes. We pay attention to breast cancer, which ranks first in the structure of oncology diseases in the Russian Federation. Nowadays, there are only a few studies devoted to the changes in the autonomic nervous system in patients with breast cancer during anticancer drug therapy, taking into account the disease progress and clinical features, as well as methods for dysfunction remodeling. The article analyzes a number of scientific information sources that can help to study various forms of autonomic neuropathy in patients with breast cancer and allow assessing the use of medical rehabilitation for such patients. Key words: autonomic nervous system, autonomic neuropathy, breast cancer, antitumor drug therapy. При изучении онкологического заболевания необходимо не только оценивать его характер, течение и исход в зависимости от локального процесса, но и учитывать общее состояние организма, так как множественное поражение органов имеет прогностическое значение и определяет исход заболевания. Следует рассматривать все механизмы и структуры, которые оказывают интегративное и гомеостатическое действие на организм в целом. Одной из таких структур является вегетативная нервная система. Традиционно вегетативная нервная система рассматривалась в аспекте 3 составляющих: симпатической, парасимпатической и кишечной. Однако в последнее время на первый план вышли представления о нейроэндокринных и нейроиммунных системах, обосновывающие расширение значения понятия «автономность нервной системы». При поражении автономной нервной системы возникает дисрегуляция непроизвольных функций организма, развивается автономная нейропатия. Выделяют кардиоваскулярную, гастроинтестинальную, урогенитальную, судомоторную формы автономной нейропатии, которые характеризуются определенными изменениями при различных патологических состояниях организма, особенно при злокачественных процессах. Фокус нашего научного внимания был направлен на рак молочной железы, который занимает первое место в структуре онкологических заболеваний в Российской Федерации. В литературе представлены немногочисленные исследования, отражающие изменения состояния вегетативной нервной системы у больных раком молочной железы в процессе противоопухолевой лекарственной терапии с учётом характера течения и клинических особенностей болезни, а также методы рациональной коррекции её дисфункции. В статье приведен анализ ряда научных источников, которые могут помочь в исследовании различных форм автономной нейропатии у больных раком молочной железы и позволят оценить возможность применения медицинской реабилитации для данной категории пациентов. Ключевые слова: вегетативная (автономная) нервная система, автономная нейропатия, рак молочной железы, противоопухолевая лекарственная терапия.


2021 ◽  
Vol 2-3 (35-36) ◽  
pp. 8-15
Author(s):  
V. Serhiyenko ◽  
◽  
M. Hotsko ◽  
S. Azhmi ◽  
O. Serhiyenko ◽  
...  

Introduction. Currently, there is no unified treatment algorithm of cardiac autonomic neuropathy (CAN) in patients with type 2 diabetes mellitus (T2DM). The aim of the study was to investigate the effects of simvastatin (SIM) and -3 polyunsaturated fatty acids (-3 PUFAs) on blood lipid profile and insulin resistance (IR) in patients with type 2 diabetes mellitus and definite cardiac autonomic neuropathy. Materials and methods. The study involved 72 patients with T2DM and definite CAN. Patients were divided into four groups: 1st - received standard hypoglycemic therapy - control (n = 15); 2nd (n = 22) – in addition simvastatin (SIM) 20.0 mg/q.d.; 3rd (n = 18) - in addition 1 capsule/q.d. of the ω-3 PUFAs; 4th (n = 17) - in addition SIM 10.0 mg/q.d and 1 capsule/q.d of the ω-3 PUFAs for three months. The concentration of glucose, glycated hemoglobin A1c, immunoreactive insulin (IRI), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG) in the blood were determined. Homeostasis model assessment IR (HOMA-IR), atherogenic coefficient (AC), TG/LDL-C, TG/TC, TG/LDL-C and TG and glucose index (TyG) were calculated. Results. Prescription of SIM was accompanied by a statistically significant decrease in TC, LDL-C, TG concentrations. In parallel, SIM induced a decrease of AC, TG/HDL-C, increase in HDL-C, and does not affect the IRI, HOMA-IR, TG/LDL-C, TG/TC, TC/LDL-C/HDL-C, TyG. The use of ω-3 PUFAs has contributed to a significant reduction in TG, AC, TG/LDL-C, TG/TC, TG/HDL-C, TyG index, increase in HDL-C, and was not accompanied by changes in IRI content, HOMA-IR, TC, LDL-C, and TC/LDL-C/HDL-C. The combined prescription of SIM and -3 PUFAs was accompanied by more pronounced, statistically significant changes in the blood lipid spectrum, as well as a decrease in the IRI and HOMA-IR. Conclusions. Obtained results justify the appropriateness of combined simvastatin and -3 polyunsaturated fatty acids prescription to patients with type 2 diabetes mellitus and definite cardiac autonomic neuropathy. Keywords: diabetes mellitus, cardiac autonomic neuropathy, treatment.


2021 ◽  
Vol 4 (3) ◽  
pp. 190-192
Author(s):  
Aditi Kapur ◽  
Richa Mishra ◽  
Rakesh Pilania ◽  
Sarojini Rai

Author(s):  
Ruman Basra ◽  
Nikolaos Papanas ◽  
Frederick Farrow ◽  
Janaka Karalliedde ◽  
Prashanth Vas

Sign in / Sign up

Export Citation Format

Share Document